JP Morgan Maintains Overweight on Cogent Biosciences, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Cogent Biosciences (NASDAQ:COGT) but lowers the price target from $22 to $19.
August 07, 2024 | 6:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Cogent Biosciences but lowers the price target from $22 to $19.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100